FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.36 USD
+0.02 (6.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.36 USD
+0.02 (6.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Zacks News
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.
Can FibroGen (FGEN) Climb 136% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for FibroGen (FGEN) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
FibroGen (FGEN) Meets Main Goal in Chemo-Induced Anemia Study
by Zacks Equity Research
FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia
by Zacks Equity Research
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA
by Zacks Equity Research
NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -202.08% and -68.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why FibroGen (FGEN) Might Surprise This Earnings Season
by Zacks Equity Research
FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote
by Zacks Equity Research
FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 13.33% and 1.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for FibroGen (FGEN)
by Aditi Saraogi
FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.
Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -120.69% and -25.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.
Find Strong Stocks with this First Profit Screener
by Benjamin Rains
Let's use our 'First Profit' screener to help find stocks that investors might want to consider buying after they posted positive earnings for the first time ever, or for some time...
FibroGen (FGEN) Q3 Earnings Beat Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 139.33% and -10.19%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Akebia Falls as Vadadustat Fails to Meet Safety Endpoint
by Zacks Equity Research
Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance Doses First Patient in Phase II Coronavirus Study
by Zacks Equity Research
Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.